Related Experiment Video
Updated: Sep 11, 2025
10:09
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
8.4K
Oncogenic IRF3 Signaling Promotes Diffused Large B-Cell Lymphoma Proliferation by Cyclin D3/CDK4-Dependent Cell Cycle
Bide Zhao1, Linjing Shi2, Xiao Yang1
1Department of Hematology and Scientific Research Center, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Hematological Oncology
|August 15, 2025
Summary
Interferon regulatory factor 3 (IRF3) is elevated in diffuse large B-cell lymphoma (DLBCL) and promotes cancer cell proliferation. Targeting IRF3 may offer new therapeutic strategies for DLBCL patients.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with variable response to current therapies.
- Identifying molecular drivers in refractory/relapsed DLBCL is crucial for developing novel therapeutic strategies.
- Interferon regulatory factor 3 (IRF3) is implicated in other cancers, but its role in DLBCL is largely unknown.
Purpose of the Study:
- To investigate the expression, biological role, and prognostic significance of IRF3 in DLBCL.
- To elucidate the mechanisms by which IRF3 influences DLBCL cell proliferation.
- To assess the potential of IRF3 as a therapeutic target in DLBCL.
Main Methods:
- Analysis of IRF3 expression in DLBCL patient samples.
- Assessment of DLBCL cell proliferation using MTS and EdU assays.
- Evaluation of cell cycle progression and apoptosis following IRF3 modulation (induction or knockdown).
- Mechanistic studies involving cell cycle regulatory proteins (cyclin D3, CDK4).
Main Results:
- IRF3 expression is significantly elevated in DLBCL patients and correlates with poorer clinical outcomes.
- IRF3 induction enhances DLBCL cell proliferation, while IRF3 knockdown suppresses it.
- IRF3 promotes G1/S phase transition by upregulating cyclin D3 and CDK4 expression.
Conclusions:
- IRF3 is a novel regulator of DLBCL cell proliferation.
- IRF3 controls DLBCL cell cycle progression at the G1/S transition via cyclin D3 and CDK4.
- IRF3 represents a potential therapeutic target for improving DLBCL treatment outcomes.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:38Mitogens and the Cell Cycle
6.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.7K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
01:22PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
01:33Cancer-Critical Genes I: Proto-oncogenes
9.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K